Evaluation of the HeartLogic Diagnostic in Optimizing Guideline-directed Medical Therapy in Patients With Congestive Heart Failure and Chronically Low Ejection Fractions (EFs) (Heartlogic ISR)
HeartLogic Optimization of CHF Medications in Chronic Low EF Population: A Follow-on Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Robert Pickett, MD
- Phone Number: 615-329-5144
- Email: robert.pickett@ascension.org
Study Contact Backup
- Name: Saint Thomas Heart at Saint Thomas Midtown
- Phone Number: 615-329-5144
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Ascension St. Vincent Medical Group
-
Principal Investigator:
- Jasen Gilge, MD
-
Contact:
- Jasen Gilge, MD
- Phone Number: 317-338-6666
- Email: Jasen.gilge@ascension.org
-
Contact:
- Ascension St. Vincent Medical Group
- Phone Number: 317-338-6666
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Saint Thomas Heart at Saint Thomas Midtown
-
Principal Investigator:
- Robert Pickett, MD
-
Contact:
- Robert Pickett, MD
- Phone Number: 615-329-5144
- Email: robert.pickett@ascension.org
-
Contact:
- Saint Thomas Heart at Saint Thomas Midtown
- Phone Number: 615-329-5144
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 years or older
- EF </=35%
- Prior hospitalization within the last two years or prior decompensation to NYHA class III or IV over the last 12 months that was treated without hospitalization
- HeartLogic capable ICD or CRT-D (Patients with HeartLogic capable ICD or CRT-D can be enrolled at time of de novo implantation or generator change out or at the time of the 2 week wound check. Prior Heart logic capable ICF or CRT-D implants can be enrolled if heart failure hospitalization shows decompensation within six months (prior implants must have at least 1 year battery life)
Exclusion Criteria:
- Refuse to give consent
- Have Life expectancy of less than one-year
- Documented noncompliance that limits medication use
- Patients on Dialysis (renal insufficiency but not on dialysis is NOT an exclusion)
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Active Treatment Arm
Heart Logic threshold set to 10 (from 16) will trigger a treatment algorithm, which includes up titration of GDMT
|
Heart Logic threshold set to 10 (from 16)
|
|
Placebo Comparator: Control Arm
Heart Logic transmission of 16 or greater may be reported to the appropriate device clinic staff by Latitude transmission and then referred to the appropriate treating provider.
Medication changes will be based upon physician preference/standards. Repeat transmissions, follow-up, laboratory studies will be per physician preference.
|
Heartlogic Threshold to remain at 16, which is the normal limit.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hospitalizations
Time Frame: 365 Days
|
Number of Hospitalizations
|
365 Days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of ICD Shocks
Time Frame: 365 Days
|
Number of ICD shocks due to VT, VF and changes to AFib burden
|
365 Days
|
|
nt-ProBNP
Time Frame: 365 days
|
Changes to nt-proBNP
|
365 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Robert Pickett, MD, Ascension Health
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RTN20250021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.